Search clinical trials for: CD7CAR T cells

Total 10909 results

iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
University College, London

Active, not recruiting

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma (CAROUSEL)

Primary CNS Lymphoma

United Kingdom
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
iCell Gene Therapeutics
iCAR Bio Therapeutics Ltd. China

Recruiting

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou

Completed

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

Lung Cancer

China
Laura Johnston
National Institutes of Health (NIH)

Completed

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

Graft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant Recipient

United States
Mitchell Horwitz, MD

Completed

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematological Malignancies

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Cellular Biomedicine Group Ltd.
Shanghai Zhongshan Hospital

Unknown

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mariella Enoc

Completed

Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Leukemia Acute Myeloid - AML

Italy
Peking University
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Cancer Institute and Hospital, Chinese Academy...
UTC Therapeutics Inc.

Not yet recruiting

MSLN-targeted CAR-T Cells in Solid Tumors.

Mesothelin-positive Advanced Malignant Solid Tumors
Assistance Publique - Hôpitaux de Paris

Suspended

Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose (UVEREG)

Uveitis

France
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou

Completed

Safety and Efficiency of γδ T Cell Against Lung Cancer

Lung Cancer

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Everett Meyer
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative Syndrome

United States
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

Neoplasms | Hematologic Diseases

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Porteus, Matthew, MD
California Institute for Regenerative Medicine (CIRM)

Recruiting

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Hematologic Diseases

United States
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
University of Pennsylvania
M.D. Anderson Cancer Center

Completed

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China

Search clinical trials for: CD7CAR T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations